TY - JOUR
T1 - Long-term treatment of chronic schizophrenia with risperidone
T2 - A study with plasma levels
AU - Mauri, M. C.
AU - Laini, V.
AU - Boscati, L.
AU - Rudelli, R.
AU - Salvi, V.
AU - Orlandi, R.
AU - Papa, P.
PY - 2001
Y1 - 2001
N2 - Twenty-four chronic schizophrenic outpatients with a mean age of 37.21 years ± 9.96 SD were treated with risperidone (RSP) at the dosage of 2-9 mg/die (mean 4.46 mg/die ±1.30 SD, mean 0.06 mg/kg ± 0.01 SD) for a year. Clinical evaluation was assessed with the Brief Psychiatric Rating Scale(BPRs), Positive and Negative Symptoms scale (PANSS), Extrapyramidal Side Effects Rating Scale (EPSE) and a checklist for Anticholinergic Side Effects (ACS) at TO, then after 1 (T1), 2 (T2), 3 (T3), 6 (T6), 9 (T9) and 12 (T12) months. RSP and 9-hydroxy-risperidone (90H-RSP) plasma levels were determined at T12 by the HPLC method. BPRS and PANSS mean values showed a significant improvement during the study. No correlation between RSP dosage (mg/kg) and RSP, 90H-RSP plasma levels Or active moiety resulted. A positive correlation between age and active moiety was Observed. A positive correlation between RSP and 90H-RSP plasma levels was observed. A curvilinear relationship between active moiety and PANSS improvement (%) was observed. Patients with the higher PANSS amelioration showed RSP + 90H-RSP plasma levels ranging from 15 to 30 ng/mL. RSP seems to be quite an effective drug. It Seems, however, difficult to devise appropriate dose schedules and plasma level determination seems to be necessary in some cases,
AB - Twenty-four chronic schizophrenic outpatients with a mean age of 37.21 years ± 9.96 SD were treated with risperidone (RSP) at the dosage of 2-9 mg/die (mean 4.46 mg/die ±1.30 SD, mean 0.06 mg/kg ± 0.01 SD) for a year. Clinical evaluation was assessed with the Brief Psychiatric Rating Scale(BPRs), Positive and Negative Symptoms scale (PANSS), Extrapyramidal Side Effects Rating Scale (EPSE) and a checklist for Anticholinergic Side Effects (ACS) at TO, then after 1 (T1), 2 (T2), 3 (T3), 6 (T6), 9 (T9) and 12 (T12) months. RSP and 9-hydroxy-risperidone (90H-RSP) plasma levels were determined at T12 by the HPLC method. BPRS and PANSS mean values showed a significant improvement during the study. No correlation between RSP dosage (mg/kg) and RSP, 90H-RSP plasma levels Or active moiety resulted. A positive correlation between age and active moiety was Observed. A positive correlation between RSP and 90H-RSP plasma levels was observed. A curvilinear relationship between active moiety and PANSS improvement (%) was observed. Patients with the higher PANSS amelioration showed RSP + 90H-RSP plasma levels ranging from 15 to 30 ng/mL. RSP seems to be quite an effective drug. It Seems, however, difficult to devise appropriate dose schedules and plasma level determination seems to be necessary in some cases,
KW - 9-hydroxy-risperidone
KW - Pharmacokinelics
KW - Plasma levels
KW - Risperidone
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=0035102075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035102075&partnerID=8YFLogxK
U2 - 10.1016/S0924-9338(00)00536-8
DO - 10.1016/S0924-9338(00)00536-8
M3 - Article
C2 - 11246293
AN - SCOPUS:0035102075
VL - 16
SP - 57
EP - 63
JO - Psychiatrie et Psychobiologie
JF - Psychiatrie et Psychobiologie
SN - 0924-9338
IS - 1
ER -